Novo Nordisk AS (MEX:NOVOBN) Research & Development: MXN148,470 Mil (TTM As of Mar. 2026)


MEX:NOVOBN Novo Nordisk AS MEX:NOVOBN
79 GF Score
Price MXN810.00
GF Value MXN2,387.36
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Research & Development?

Novo Nordisk AS MEX:NOVOBN +3.85% 79 Research & Development is MXN148,470 Mil as of Mar. 2026. GuruFocus rates MEX:NOVOBN with a GF Score™ of 79/100 and a GF Value™ of MXN2,387.36 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Novo Nordisk AS's Research & Development for the three months ended in Mar. 2026 was MXN28,684 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was MXN148,470 Mil.

Novo Nordisk AS  (MEX:NOVOBN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Novo Nordisk AS Research & Development Related Terms

Novo Nordisk AS Research & Development Historical Data

* Premium members only.

The historical data trend for Novo Nordisk AS's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS Research & Development Chart

Novo Nordisk AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55,398.09 66,755.94 80,572.30 140,740.32 146,901.83

Novo Nordisk AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30,565.87 34,031.13 44,405.14 41,350.10 28,683.63
MEX:NOVOBN
79GF Score
Novo Nordisk AS MEX:NOVOBN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN148,470 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN148,470 Mil mean?
Novo Nordisk AS (MEX:NOVOBN) has a Research & Development of MXN148,470 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's Research & Development too high?
Novo Nordisk AS's current Research & Development is MXN148,470 Mil. Overall, Novo Nordisk AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Research & Development compare to LLY and JNJ?
Novo Nordisk AS's Research & Development of MXN148,470 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Novo Nordisk AS and its competitors. Novo Nordisk AS's current Research & Development is MXN148,470 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NOVOBN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,387.36, compared to a current price of MXN810.00 — trading 66.1% below its estimated fair value. The current Research & Development is MXN148,470 Mil. Novo Nordisk AS's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NOVOBN), the current Research & Development is MXN148,470 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novo Nordisk AS (MEX:NOVOBN) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of MXN810.00 is trading 66.1% below its estimated GF Value™ of MXN2,387.36. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for MEX:NOVOBN:

  • Research & Development: MXN148,470 Mil
  • GF Value™: MXN2,387.36 vs. price of MXN810.00 (66.1% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the MEX:NOVOBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
79GF Score

Get the complete analysis for MEX:NOVOBN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN810.00
Price
MXN2,387.36
GF Value